November 19, 2023

Glutagen honoured with Outstanding & Innovative New Consumer Healthcare Product Award

We are thrilled to announce that Glutagen has received the 2023 Outstanding & Innovative New Consumer Healthcare Product award for the product GluteGuard. This accolade recognises Glutagen’s cutting-edge innovation and commitment to improving the lives of those on a gluten free diet.

Presented annually by Consumer Healthcare Products (CHP) Australia, this award celebrates products that demonstrate exceptional innovation and contribute to excellence in the consumer healthcare products industry. GluteGuard stood out due to its revolutionary approach to helping consumers manage a gluten free diet, which the judges commented as being ‘evident by the remarkable customer testimonials’.

GluteGuard is a tablet taken before meals when gluten contamination is uncertain. What sets it apart is that it’s the only clinically proven^ product formulated with Caricain, an innovative, naturally derived enzyme from the skin of the papaya fruit. This unique enzyme effectively breaks down harmful gluten peptides before they interact with the intestinal lining. The product addresses a critical need for those on a gluten free diet, helping to protect from symptoms* and the subsequent disruption on day-to-day life caused by accidental gluten ingestion. This award reaffirms GluteGuard’s position as a game-changer in the consumer healthcare market.

We are incredibly honoured to receive the 2023 Outstanding & Innovative New Consumer Healthcare Product award,” says Cass Green, Glutagen’s Product Manager. “Changing the way the world manages a gluten free diet, by not only developing a new product, but a whole new solution doesn’t come without its challenges. Now, after being available in Australian pharmacies for a year and hearing how GluteGuard has changed the lives of tens of thousands of Australians for the better, that truly is our driving force, and we can’t wait to take this Australian innovation to the rest of the world.”

No mention of GluteGuard’s innovation can be without honouring Professor Hugh Conell (OAM), the pioneer of enzyme therapy in gluten related disorders, who was instrumental in the development of GluteGuard.

The award ceremony in Sydney on November 2nd celebrated Glutagen alongside other healthcare leaders, showcasing excellence in marketing and sales, new products, manufacturing innovation, and sustainability initiatives in the consumer healthcare products industry.

“The consumer healthcare products industry promotes self-care, healthy lifestyles, and healthy choices. This is at the core of who we are, so our judges are always looking to reward leading-edge creative work, innovation, and best practice in self-care. This year, all entries were outstanding.” Dr Deon Schoombie, CHP Australia Chief Executive Officer.


References:
^Cornell JH et al. 2016 IJCD Vol. 4, No 2 p:40-47. Zebrowska A et al. 2014 IJCD Vol. 2, No 2 p:58-63. These clinical studies were funded by Glutagen Pty Ltd.
*GluteGuard helps protect those with medically diagnosed gluten sensitivity from symptoms of accidental gluten ingestion. Always read the label and follow the directions for use. For use only in conjunction with a gluten free diet.
Related

Related Posts

Glutagen expands into Canada with the launch of GluteGuard